Table 2.
Summary of the effect of various drugs used in this study that modulate gp91phox- and cAMP PKA–dependent proton channels
| Drug | mM | Intracellular targets |
| Zn2+ | 0–20 | ↓Proton channels |
| DEPC | 0–10 | ↓Proton channels |
| 8-CPT-cAMP | 15 | ↑Proton channel activity |
| 8-CPT-cGMP | 15 | |
| H2O2 | 0–15% | ↑Proton channel activity |
| Nitrazepam | 0.5 | Synthetic substrate for intracellular NADPH oxidase |
| PMA | 0.25 | ↑Proton channels in phagocytes |
| Rp-8-CPT-cAMPS | 4.5 | ↓PKA I and II |
PMA (activates protein kinase C); 8-CPT-cAMP, 8-(4-chlorophenylthio) adenosine-3′-5′-cyclic monophosphate (membrane permeable cAMP analog); Rp-8-CPT-cAMPS, 8-(4-chlorophenylthio)-adenosine-3′-5′-cyclic monophospho-rothioate (competitive inhibitor of PKA I and II); 8-CPT-cGMP, 8-(4-chlorophenylthio) guanosine-3′-5′-cyclic monophosphate (membrane permeable cGMP analog); and DEPC (modification reagent for His and Tyr residues in proteins). All reagents were obtained from Sigma.